Upgrade to SI Premium - Free Trial

Ultragenyx Pharma (RARE)

25.38 +1.03 (4.23%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Form 4 Ultragenyx Pharmaceutica For: Jun 15 Filed by: Sanders Corazon (Corsee) D. June 15, 2026 6:51 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: Jun 15 Filed by: Parschauer Karah Herdman June 15, 2026 6:46 PM - SEC Filing Form 144 Ultragenyx Pharmaceutica Filed by: Parschauer Karah Herdman June 15, 2026 4:51 PM - SEC Filing Form 144 Ultragenyx Pharmaceutica Filed by: Sanders Corazon (Corsee) D. June 15, 2026 4:12 PM - SEC Filing Form S-8 Ultragenyx Pharmaceutica June 12, 2026 1:40 PM - SEC Filing Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference June 3, 2026 4:30 PM - StreetInsider Form 4 Ultragenyx Pharmaceutica For: Jun 01 Filed by: Horn Howard June 1, 2026 7:12 PM - SEC Filing Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard June 1, 2026 4:09 PM - SEC Filing Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) May 22, 2026 4:30 PM - StreetInsider Ultragenyx Pharma (RARE) PT Raised to $96 at Cantor Fitzgerald May 21, 2026 6:36 AM - StreetInsider Ultragenyx Pharma (RARE) PT Lowered to $72 at JPMorgan May 20, 2026 7:37 AM - StreetInsider Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Fust Matthew K May 18, 2026 6:51 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: SULIMAN SHEHNAAZ May 18, 2026 6:41 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Ray Amrit May 18, 2026 6:40 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Sanders Corazon (Corsee) D. May 18, 2026 6:39 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: NARACHI MICHAEL May 18, 2026 6:36 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: WELCH DANIEL G May 18, 2026 6:23 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: May 14 Filed by: Dunsire Deborah May 18, 2026 6:21 PM - SEC Filing Form 144 Ultragenyx Pharmaceutica Filed by: SULIMAN SHEHNAAZ May 18, 2026 4:50 PM - SEC Filing Form 8-K Ultragenyx Pharmaceutica For: May 14 May 18, 2026 2:15 PM - SEC Filing Form SCHEDULE 13G Ultragenyx Pharmaceutica Filed by: STATE STREET CORP May 12, 2026 12:13 PM - SEC Filing Ultragenyx Pharma (RARE) PT Lowered to $43 at Guggenheim May 8, 2026 7:22 AM - StreetInsider Ultragenyx to Participate at Bank of America’s 2026 Healthcare Conference May 6, 2026 4:30 PM - StreetInsider Form 4 Ultragenyx Pharmaceutica For: May 05 Filed by: Crombez Eric May 6, 2026 2:51 PM - SEC Filing Ultragenyx Pharma (RARE) PT Raised to $47 at Wells Fargo May 6, 2026 8:49 AM - StreetInsider Form 10-Q Ultragenyx Pharmaceutica For: Mar 31 May 6, 2026 6:03 AM - SEC Filing Ultragenyx Pharma (RARE) Misses Q1 EPS by 38c, provides guidance May 5, 2026 4:34 PM - StreetInsider Form 8-K Ultragenyx Pharmaceutica For: May 05 May 5, 2026 4:07 PM - SEC Filing Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update May 5, 2026 4:01 PM - Globe NewsWire Form 4 Ultragenyx Pharmaceutica For: May 01 Filed by: Horn Howard May 4, 2026 5:36 PM - SEC Filing Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard May 1, 2026 4:07 PM - SEC Filing Form DEFA14A Ultragenyx Pharmaceutica April 30, 2026 4:06 PM - SEC Filing Form SCHEDULE 13G Ultragenyx Pharmaceutica Filed by: VANGUARD PORTFOLIO MANAGEMENT LLC April 29, 2026 3:48 PM - SEC Filing Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update April 29, 2026 8:00 AM - Globe NewsWire Ultragenyx Pharma (RARE) PT Lowered to $43 at Barclays April 29, 2026 2:18 AM - StreetInsider Form 4 Ultragenyx Pharmaceutica For: Apr 22 Filed by: Huizenga Theodore Alan April 24, 2026 4:40 PM - SEC Filing Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) April 24, 2026 4:30 PM - StreetInsider Form 4 Ultragenyx Pharmaceutica For: Apr 16 Filed by: KAKKIS EMIL D April 20, 2026 5:20 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: Apr 16 Filed by: Huang Dennis Karl April 20, 2026 5:18 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: Apr 16 Filed by: Pinion John Richard April 20, 2026 5:16 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: Apr 16 Filed by: Parschauer Karah Herdman April 20, 2026 5:15 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: Apr 16 Filed by: Harris Erik April 20, 2026 5:13 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: Apr 16 Filed by: Crombez Eric April 20, 2026 5:11 PM - SEC Filing Form 4 Ultragenyx Pharmaceutica For: Apr 16 Filed by: Horn Howard April 20, 2026 5:09 PM - SEC Filing Ultragenyx Pharma (RARE) PT Raised to $67 at Morgan Stanley April 16, 2026 8:08 AM - StreetInsider Form 4 Ultragenyx Pharmaceutica For: Apr 01 Filed by: Horn Howard April 2, 2026 6:20 PM - SEC Filing Morgan Stanley on Ultragenyx Pharma (RARE): BLA submission acceptance removes key overhang April 2, 2026 12:00 PM - StreetInsider Leerink Partners on Ultragenyx Pharma (RARE): FDA BLA acceptance positions co for two approvals, $150M oppty April 2, 2026 10:46 AM - StreetInsider Form 8-K Ultragenyx Pharmaceutica For: Apr 02 April 2, 2026 8:45 AM - SEC Filing FDA accepts Ultragenyx resubmission for rare disease gene therapy UX111 April 2, 2026 8:31 AM - StreetInsider Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) April 2, 2026 8:30 AM - Globe NewsWire Form 144 Ultragenyx Pharmaceutica Filed by: Horn Howard April 1, 2026 4:13 PM - SEC Filing Form 8-K Ultragenyx Pharmaceutica For: Mar 30 March 30, 2026 8:45 AM - SEC Filing Ultragenyx receives FDA clearance for GNE myopathy drug trial March 30, 2026 8:32 AM - StreetInsider Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy March 30, 2026 8:30 AM - StreetInsider Form ARS Ultragenyx Pharmaceutica For: Dec 31 March 27, 2026 4:32 PM - SEC Filing Form DEFA14A Ultragenyx Pharmaceutica March 27, 2026 4:32 PM - SEC Filing Form DEF 14A Ultragenyx Pharmaceutica For: May 14 March 27, 2026 4:31 PM - SEC Filing Form SCHEDULE 13G/A Ultragenyx Pharmaceutica Filed by: VANGUARD GROUP INC March 27, 2026 1:55 PM - SEC Filing Goldman Sachs Downgrades Ultragenyx Pharma (RARE) to Neutral March 24, 2026 2:32 AM - StreetInsider Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 20, 2026 4:30 PM - StreetInsider Ultragenyx Pharmaceutical Inc. Notice of April 6, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline March 17, 2026 10:58 PM - Globe NewsWire RARE Shareholder Alert: Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Investors With Losses May Join -- The Gross Law Firm March 17, 2026 9:00 AM - PR NewsWire Full Article List